iCLAS™ for Persistent Atrial Fibrillation
Completed · Not applicable · NCT04061603
Conditions: Persistent Atrial Fibrillation
At a glance
- Research payments reported, 2025
- $16,100
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 215
About the trial
- Sponsor
- Adagio Medical
- Tested
- Adagio AF Cryoablation System (iCLAS™) (device)
- Dates
- Started 2019-12-09; completion 2024-08-30
- Results posted
- Yes
Clinical study to evaluate the safety and efficacy of the Adagio AF Cryoablation System (iCLAS™) in the ablation treatment of symptomatic, persistent atrial fibrillation (PsAF). Data will be used to support a pre-market application (PMA)
From ClinicalTrials.gov, last updated 2026-08-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Adagio Medical, Inc. reported $16,100 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Feinstein Institutes for Medical Research $16,100
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.